Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1344 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Intervention not reported

Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 97 participants
Low

Intervention not reported

Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1956 participants
Very low

Intervention not reported

Recurrence ‐ AIs · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 175 participants
Very low

Intervention not reported

Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Very low

Intervention not reported

Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Low

Intervention not reported

Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Low

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
HR 0.68 [0.6, 0.76]
6 studies · 2111 participants
Moderate